Document is current
Any future updates will be listed below
-
Authors
Cardona-Ospina, Jaime A. https://orcid.org/0000-0003-3996-2293
Roy, Vicky https://orcid.org/0000-0002-5064-1098
Marcano-Jiménez, Dorca E. https://orcid.org/0009-0004-6826-9580
Bos, Sandra https://orcid.org/0000-0001-5036-0336
Duarte, Elias
Zambrana, José V.
Bal, Agamjot https://orcid.org/0009-0008-5717-4729
An, Boyeong K. https://orcid.org/0009-0006-6018-2100
Dias, Antonio Gregorio Jr https://orcid.org/0000-0003-4392-4206
Zhiteneva, Julia
Huffaker, Julia https://orcid.org/0009-0008-8939-1971
Montenegro, Carlos
Kuan, Guillermina
Ramos-Benitez, Marcos J.
Balmaseda, Angel
Alter, Galit https://orcid.org/0000-0002-7680-9215
Harris, Eva https://orcid.org/0000-0002-7238-4037
- License Information
-
More Information
Article History
Received: 21 March 2025
Accepted: 7 November 2025
First Online: 2 January 2026
Competing interests
: E.H.’s laboratory received research funds from Takeda Vaccines Inc. to test samples from vaccine recipients. E.H. served on one-time advisory boards for Merck and Takeda. G.A. was an employee of Moderna Therapeutics and holds equity in Leyden Labs and Systems Seromyx. The other authors declare no competing interests.
